A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Status:
Completed
Trial end date:
2017-10-11
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to
vehicle for the treatment of the signs and symptoms of allergic conjunctivitis